John Libbey Eurotext

Hépato-Gastro & Oncologie Digestive

MENU

Treatment of patients with acute severe ulcerative colitis refractory to steroids Volume 18, supplement 5, Septembre 2011

Figures

See all figures

Author
CHU de Bordeaux, hôpital Haut-Lévêque, service d’hépato-gastroentérologie et nutrition, 33600 Pessac, France, Inserm U853, université Bordeaux-II, laboratoire de bactériologie, 33000 Bordeaux, France

Intravenous steroids remain the mainstay of conventional therapy for acute severe ulcerative colitis. However, their efficacy is still limited to 67%. A colonic superinfection by CMV or Clostridium difficile should be rule out before starting second line therapy. To avoid urgent colectomy two medical options are available at this step: cyclosporine and infliximab. The first comparing trial – so called CYSIF – has been conducted by the GETAID and recently achieved. The CYSIF study could not demonstrate that cyclosporine was more effective than infliximab in patients with acute severe ulcerative colitis refractory to intravenous steroids. The benefit of a third line of medical therapy is probably limited when compared to safety. Therefore, colectomy should be considered at this time.